|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||||||
| Current Assets: | ||||||||||||
| Cash | ||||||||||||
| Restricted cash | ||||||||||||
| Prepaid expenses | ||||||||||||
| Income taxes receivable | ||||||||||||
| Franchise tax receivable | ||||||||||||
| Total Current Assets | ||||||||||||
| Cash held in the Trust Account | ||||||||||||
| Cash equivalents held in the Trust Account | ||||||||||||
| Available-for-sale debt securities held in Trust Account, at fair value (no allowance for credit losses, amortized cost $185,871,867) | ||||||||||||
| Other assets | ||||||||||||
| Total Assets | ||||||||||||
| Liabilities and Stockholders’ Deficit: | ||||||||||||
| Current Liabilities: | ||||||||||||
| Accrued expenses | ||||||||||||
| Payables to related party | ||||||||||||
| Franchise tax payable | ||||||||||||
| Excise tax payable | ||||||||||||
| Income taxes payable | ||||||||||||
| Sponsor loan – promissory notes | ||||||||||||
| Other current liability | ||||||||||||
| Payable to related party | ||||||||||||
| Total Liabilities | ||||||||||||
| Class A common stock subject to possible redemption, 5,267,634 and 14,303,581 shares issued and outstanding at redemption value of $11.27 and $10.84 per share as of September 30, 2024 and December 31, 2023, respectively | ||||||||||||
| Stockholders’ Deficit: | ||||||||||||
| Common stock value | ||||||||||||
| Class A Common Stock | ||||||||||||
| Class B Common Stock | ||||||||||||
| Total common stock value | ||||||||||||
| Class B common stock, $0.0001 par value; 40,000,000 shares authorized; 4,562,500 shares issued and outstanding as of both September 30, 2022 and December 31, 2021 | ||||||||||||
| Additional paid-in-capital | ||||||||||||
| Class B common stock, $0.0001 par value; 40,000,000 shares authorized; 120,000 and 4,562,500 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively | ||||||||||||
| Accumulated deficit | ||||||||||||
| Accumulated other comprehensive loss | ||||||||||||
| Total Stockholders’ Deficit | ||||||||||||
| Total Liabilities, Commitments and Contingencies and Stockholders’ Deficit |
Loading...
